|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Follow-up of intestinal metaplasia in the stomach: When, how and why显示文摘Gastric cancer remains the second most frequent cause of cancer-related mortality in the world. Screening programs in some Asian countries are impractical in the majority of other countries worldwide. Therefore, follow-up of precancerous lesions is advisable for secondary gastric cancer prevention. Intestinal metaplasia (IM) is recognized as a precancerous lesion for gastric cancer, increasing the risk by 6-fold. IM is highly prevalent in the general population, being detected in nearly 1 of every 4 patients undergoing upper endoscopy. The IM prevalence rate is significantly higher in patients with Helicobacter pylori (H. pylori) infection, in first-degree relatives of gastric cancer patients, in smokers and it increases with patient age. IM is the 'breaking point' in the gastric carcinogenesis cascade and does not appear to regress following H. pylori eradication, although the cure of infection may slow its progression. Gastric cancer risk is higher in patients with incomplete-type IM, in those with both antral and gastric body involvement, and the risk significantly increases with IM extension over 20% of the gastric mucosa. Scheduled endoscopic control could be cost-effective in IM patients, depending on the yearly incidence of gastric cancer in IM patients, the stage of gastric cancer at diagnosis discovered at surveillance, and the cost of endoscopy. As a pragmatic behavior, yearly endoscopic control would appear justified in all IM patients with at least one of these conditions: (1) IM extension > 20%; (2) the presence of incomplete type IM; (3) first-degree relative of gastric cancer patients; and (4) smokers. In the remaining IM patients, a less intensive (2-3 years) could be proposed. | Angelo Zullo Cesare Hassan Adriana Romiti Michela Giusto Carmine Guerriero Roberto Lorenzetti Salvatore MA Campo Silverio Tomao | 2012 | World Journal of Gastrointestinal Oncology2012，4，3： | 25 |
| 2 | Brainstem gliomas--retrospective analysis of 86 patients显示文摘 | Ueoka DI Nogueira J Campos JC Maranhao Filho P Ferman S Lima MA | 2009 | 中国神经肿瘤杂志2009，7，3： | 3 |
| 3 | Rifaximin therapy and hepatic encephalopathy:Pros and cons显示文摘Hepatic encephalopathy(HE) is the second most common major complication in cirrhotics and it significantly impacts quality of life.Therapeutic approaches for HE treatment and prevention mainly continue to rely on ammonia-lowering strategies and non-absorbable disaccharides are currently considered the cornerstone therapy.Non-absorbable antibiotics,such as neomycin and paramomycin,are effective in treatment of acute HE episodes but their prolonged use for recurrence prevention is hampered by possible side-effects.To overcome these limitations,rifaximin use has been proposed.Rifaximin has been shown to be not superior to non-absorbable disaccharides for either HE treatment or prevention,with a similar incidence of side-effects.Cirrhosis significantly increases rifaximin absorption and this could be a cause for concern.Following long-term rifaximin therapy,Clostridium difficile colitis has been observed and Candida albicans has been isolated from 20% of patients.In addition,selection of resistant mutants of both Gram-negative and-positive bacteria in the gastrointestinal tract cannot be definitely ruled out.Electrolyte alterations(sodium and potassium) have been reported during rifaximin therapy,a warning for its long-term use in cirrhotics.Moreover,a potential interference with vitamin K production should be considered which could further impair the already altered clotting status of these patients.The therapeutic cost of rifaximin is markedly higher than non-absorbable disaccharides.While waiting for further safety data,caution should be used to limit the use of rifaximin therapy for a very short-term period in selected HE cirrhotics not responding to nonabsorbable disaccharides. | Angelo Zullo Cesare Hassan Lorenzo Ridola Roberto Lorenzetti Salvatore MA Campo Oliviero Riggio | 2012 | World Journal of Gastrointestinal Pharmacology and Therapeutics2012，3，4： | 2 |
| 4 | Anti nucleosome antibodies in patients with juvenile systemic lupus erythematosus显示文摘 | Kiss MH Scheinberg MA | 2006 | Lupus2006，15，8： | 1 |
| 5 | Bleeding Peptic Ulcer in the Elderly: Risk Factors and Prevention Strategies 显示文摘 | Zullo Angelo Hassan Cesare Campo Salvatore MA | 2007 | Drags &Aging2007，24，10： | 1 |
| 6 | Stimula-tion of toll-like receptor 2 by coxiella burnetii is requiredfor macrophage production of pro-inflammatory cytokinesand resistance to infection 显示文摘 | Zamboni DS Campos MA Torrecilhas AC | 2004 | J Biol Chem2004，279，54： | 1 |
| 7 | Circulating angiogenic factors and urinary prolactin as predictors of adverse outcomes in women with preeclampsia显示文摘 | Lea(n)os MA Campos GI Ramírez V KL | 2013 | Hypertension2013，61，5： | 1 |
| 8 | Acute Lung Injury Outside of the ICU显示文摘 | Quartin AA Campos MA Maldonado DA | 2009 | Chest2009，135，： | 1 |
| 9 | Comparative study of two models that use biochemical parameters for the noninvasive diagnosis of fibrosis in patients with hepatitis C显示文摘 | Romero Gomez M Rami rez Marti n del Campo M Otero MA | 2005 | Med Clin2005，124，20： | 1 |
| 10 | Activationof TLR2 and TLR4 by glycosylphosphatidylinositols derived fromToxoplasma gondii显示文摘 | Debierre-Grockiego F Campos MA Azzouz N | 2007 | J Immunol2007，179，2： | 1 |
| 11 | Role of Toll -like receptor 4 in induction of cell - mediated immunity and resistance to Brucelia abortus infection in mice显示文摘 | Campos MA Rosinha GM Almeida IC | 2004 | Infect Immun2004，72，： | 1 |
| 12 | Adenoid cystic carcinoma of tile larynx, case report and literature review显示文摘 | Damborenea TJ Campos del Alamo MA Marin GJ | 1999 | An Otorrinolaringol Ibero Am1999，26，3： | 1 |
| 13 | Oral transmission of HIV, reality or fiction? An update显示文摘 | Campo J Perea MA del Romero J | 2006 | Oral Dis2006，12，3： | 1 |
| 14 | Activation of Toll-like receptor-2 by glycosylphosphatidylinositol anchors from a protozoan parasite显示文摘 | Campos MA Almeida IC Takeuchi O | 2001 | J Immunol2001，167，1： | 1 |
| 15 | Antinucleosome antibo- dies in patients with juvenile systemic lupus erythematosus 显示文摘 | Campos LM Kiss MH Scheinberg MA | 2006 | Lupus2006，15，8： | 1 |
| 16 | Pulmonary artery rupture duced by a pulmonary artery catheter:a case report and review of the terature显示文摘 | Abreu AR Campos MA Krieger BP | 2004 | Intensive Care Med2004，19，5： | 1 |
| 17 | Comparison of adenovirus fiber, protein Ⅸ, and hexon capsomeres as scaffolds for vector purification and cell targeting 显示文摘 | Campos SK Barry MA | 2006 | Virology2006，349，2： | 1 |
| 18 | Activation of TLR2 and TLR4 by glycosylphosphatidylinositols derived from Toxoplasma gondii显示文摘 | Debierre-Grockiego F Campos MA Azzouz N | 2007 | J Immunol2007，179，1： | 1 |
| 19 | Follow-up study in local allergic rhinitis shows a consistent entity not evolving to systemic allergic rhinitis显示文摘 | Rond6n C Campo P Zambonino MA | 2014 | J Allergy Clin Immunol2014，133，4： | 1 |
| 20 | Florid reactive periostitis ossificans of the distal ulna显示文摘 | Porcel L6pez MT Fernández Gil MA Campos de Orellana A | | 0，，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员